RecruitingHead and Neck Cancer
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to determine if panitumumab-IRDye800 is effective in identifying cancer, compared to surrounding normal tissue, and the further characterize the safety profile of this drug.
Sponsor: University of Alabama at Birmingham
You may qualify if…
- ✓ 1. Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck
- ✓ 2. Diagnosis of any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Patients with recurrent disease or a new primary will be allowed.
- ✓ 3. Planned standard of care surgery with curative intent for squamous cell carcinoma
- ✓ 4. Male or female patients age ≥ 18 years
- ✓ 5. Have life expectancy of more than 12 weeks
- ✓ 6. Karnofsky performance status of at least 70% or ECOG/Zubrod level 1
- ✓ 7. Have acceptable hematologic status, coagulation status, kidney function, and liver function including the following clinical results:
- ✓ 1. Hemoglobin ≥ 9 gm/dL
You may not qualify if…
- ✕ 1. Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
- ✕ 2. Had within 6 months prior to enrollment: MI, CVA, or uncontrolled CHF
- ✕ 3. History of infusion reactions to any monoclonal antibody therapies
- ✕ 4. Women who are pregnant or breast-feeding
- ✕ 5. Evidence of QT prolongation on pretreatment ECG (greater than 440 ms in males or greater than 450 ms in females)
- ✕ 6. Magnesium or potassium lower than the normal institutional values
- ✕ 7. Patients receiving Class IA (quinidine, procanamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
- ✕ 8. Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
Where it's recruiting
Alabama
Birmingham
Source: ClinicalTrials.gov · NCT04511078 · last updated 2025-12-24